The value of axi-cel as a second-line treatment in R/R LBCL

Axi-cel as second-line therapy for R/R large B-cell lymphomaПодробнее

ALYCANTE: axi-cel as second-line therapy for transplant-ineligible patients with R/R LBCLПодробнее

Axi-cel improves survival in early r/r large B-cell lymphomaПодробнее

ZUMA-7: Axi-cel in r/r large B-cell lymphomaПодробнее

ZUMA-7: overall survival benefit of axi-cel over SOC in second-line LBCLПодробнее

TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCLПодробнее

Matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2L treatment of R/R LBCLПодробнее

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCLПодробнее

Insights into the ZUMA-23 trial: axi-cel in frontline high-risk LBCLПодробнее

Second-line CAR-T therapy in B-cell lymphomaПодробнее

New algorithm for second-line DLBCL: the role of CAR-T therapyПодробнее

ZUMA-7 subgroup analysis: axi-cel vs SOC in elderly patients with R/R LBCLПодробнее

Standard-of-care setting results of axi-cel in R/R large B-cell lymphomaПодробнее

CAR-T & bispecific antibodies in second-line DLBCLПодробнее

Frederick Locke on Axi-cel and ZUMA-7Подробнее

The use of clonoSEQ to monitor MRD in patients with LBCL treated with axi-cel in ZUMA-7Подробнее

Rationale of TRANSFORM: liso-cel vs SOC in patients with high-risk R/R NHLПодробнее

Real-world comparison of axi-cel and tisa-cel in R/R DLBCLПодробнее

Shorter time from leukapheresis to infusion of axi-cel shows better CR and OS in r/r LBCLПодробнее